Evidence map›Paper›PMID 35865733›Full record

ArticleResearch and practice in thrombosis and haemostasis2022

Novel ELISA for the specific detection of protease NEXIN-1 in human biological samples.

Laurence Venisse, Déborah François, Célina Madjène, Els Brouwers, Emmanuelle de Raucourt, Yacine Boulaftali, Paul Declerck, Véronique Arocas, Marie-Christine Bouton

Open access · goldAbstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Novel ELISA for the specific detection of protease NEXIN-1 in human biological samples.Research and practice in thrombosis and haemostasis · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Laurence VenisseUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Déborah FrançoisUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Célina MadjèneUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Els BrouwersLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium.
Emmanuelle de RaucourtUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Yacine BoulaftaliUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Paul DeclerckLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium.ORCID https://orcid.org/0000-0003-1259-9105
Véronique ArocasUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.
Marie-Christine BoutonUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM U1148-LVTS Paris France.ORCID https://orcid.org/0000-0001-5092-7363
Inserm · FRResearch & Diagnostic Antibodies (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Serpin E2 or protease nexin-1 (PN-1) is a glycoprotein belonging to the serpin superfamily, whose function is closely linked to its ability to inhibit thrombin and proteases of the plasminergic system. Objectives: In the absence of specific quantitative methods, an ELISA for the quantification of human PN-1 was characterized and used in biological fluids. Methods: The ELISA for human PN-1 was developed using two monoclonal antibodies raised against human recombinant PN-1. PN-1 was quantified in plasma, serum, platelet secretion from controls and patients with hemophilia A and in conditioned medium of aortic tissue. Results: A linear dose-response curve was observed between 2 and 35 ng/mL human PN-1. Intra- and interassay coefficients of variation were 6.2% and 11.1%, respectively. Assay recoveries of PN-1 added to biological samples were ≈95% in plasma, ≈97% in platelet reaction buffer, and ≈93% in RPMI cell culture medium. Levels of PN-1 secreted from activated human platelets from controls was similar to that of patients with hemophilia A. PN-1 could be detected in conditioned media of aneurysmal aorta but not in that of control aorta. Conclusion: This is the first fully characterized ELISA for human serpin E2 level in biological fluids. It may constitute a relevant novel tool for further investigations on the pathophysiological role of serpin E2 in a variety of clinical studies.

Indexed as

ELISAhemophilia Ahumanplateletsserpin

Identifiers

PMID35865733
PMCPMC9294866
OpenAlexW4285806128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.